Key facts
- It has raised $14.3M; the latest was Later Stage VC ($14.3M) in Jan 2026.
- Notable investors include Huatai Zijin Investment, Huzhou Jinfu Investment, Hangzhou Donglu Asset Management, Huzhou Xinchuangke Venture Capital, Shanghai Hongmai Investment Management — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Huarong Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Huarong Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Huarong Bio
Developer and producer of enzymes and related biological raw materials designed for health care, cosmetics and medicine production. With genetic engineering, high-throughput screening, fermentation-transformation and supercritical extraction and other bio-technologies, the company's products include nutritional and health material series enzymes materials, providing health care, cosmetics and medical industry clients with high-quality raw-material supplies.
- Sector
- Materials and Resources
- HQ
- Huzhou, China
- Founded
- 2012
- Employees
- 170
- Website
- sencl.com/
- Ownership
- Privately Held (backing)
Huarong Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Huarong Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Huarong Bio in its N-PORT filings yet. We sweep new filings monthly.